Zobrazeno 1 - 10
of 115
pro vyhledávání: '"M, Litchman"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Donald Milligan, Pier Paolo Piccaluga, Stephen Schey, M Litchman, A. Covelli, C Pfister, Stephen M. Kelsey, Giuseppe Visani, H Mayer, Robert Marcus, Alessandro Isidori, James Chang, M Malagola, R. L. Powles, F Leoni
Publikováno v:
Leukemia. 15:764-771
PSC 833 (Valspodar) can reverse multidrug resistance (MDR) in patients with hematologic malignancies, but alters the pharmacokinetics of concomitant anticancer agents. A phase I, dose-finding study was initiated to define a safe and effective regimen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70bf8ca6134b540a917e9f922cc8e401
https://doi.org/10.1038/sj.leu.2402117
https://doi.org/10.1038/sj.leu.2402117
Autor:
C. Karanes, Robert T. Dorr, William S. Dalton, Joseph O. Moore, Alan F. List, T. Pearce, J. Greer, Denise J. Roe, G. Schiller, B. Weinberger, T. M. Grogan, M. Litchman, C. Spier
Publikováno v:
Journal of Clinical Oncology. 19:1589-1599
PURPOSE: To determine the maximum-tolerated dose, pharmacokinetic interaction, and activity of PSC 833 compared with daunorubicin (DNR) and cytarabine in patients with poor-risk acute myeloid leukemia. PATIENTS AND METHODS: Patients received ara-C 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::463be03c59e33c7788a24dfb9d6dcd25
https://doi.org/10.1200/jco.2001.19.6.1589
https://doi.org/10.1200/jco.2001.19.6.1589
Autor:
Henry M. Litchman
Publikováno v:
Journal of Medical Regulation. 90:5-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2914108a46d2293afaefa1428e43f3a6
https://doi.org/10.30770/2572-1852-90.4.5
https://doi.org/10.30770/2572-1852-90.4.5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(5)
P-glycoprotein is an efflux pump for many drugs including doxorubicin and paclitaxel. This study evaluated the coadministration of these drugs with the P-glycoprotein inhibitor valspodar (PSC 833) with the aim of determining: (a) maximum tolerated do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c4f6e0f4883401e5f0e4f456cec5d5f5
https://pubmed.ncbi.nlm.nih.gov/11350887
https://pubmed.ncbi.nlm.nih.gov/11350887
Autor:
P M, Fracasso, P, Westervelt, C L, Fears, D M, Rosen, E G, Zuhowski, L A, Cazenave, M, Litchman, M J, Egorin, P, Westerveldt, C A, Fears
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 18(5)
PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of paclitaxel when given with PSC 833 (valspodar) to patients with refractory solid tumors. PATIENTS AND METHODS: Patients were initially treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41466b6a89393a830dda8ce1cd55c8ae
https://pubmed.ncbi.nlm.nih.gov/10694566
https://pubmed.ncbi.nlm.nih.gov/10694566
Autor:
R, Advani, G, Visani, D, Milligan, H, Saba, M, Tallman, J M, Rowe, P H, Wiernik, J, Ramek, K, Dugan, B, Lum, J, Villena, E, Davis, E, Paietta, M, Litchman, A, Covelli, B, Sikic, P, Greenberg
Publikováno v:
Advances in experimental medicine and biology. 457
The failure of convenional chemotherapy in relapsed or refractory and other poor risk AML patients has been linked to expression of the multidrug resistance gene (mdr 1) product P-glycoprotein (P-gp). PSC 833 is a non-competitive inhibitor of P-gp an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bfb6528a4952102cbbace20563c1f394
https://pubmed.ncbi.nlm.nih.gov/10500779
https://pubmed.ncbi.nlm.nih.gov/10500779
Autor:
R, Advani, H I, Saba, M S, Tallman, J M, Rowe, P H, Wiernik, J, Ramek, K, Dugan, B, Lum, J, Villena, E, Davis, E, Paietta, M, Litchman, B I, Sikic, P L, Greenberg
Publikováno v:
Blood. 93(3)
A potential mechanism of chemotherapy resistance in acute myeloid leukemia (AML) is the multidrug resistance (MDR-1) gene product P-glycoprotein (P-gp), which is often overexpressed in myeloblasts from refractory or relapsed AML. In a multicenter pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6052e0e0f332ca0a2b43b02dff243c9e
https://pubmed.ncbi.nlm.nih.gov/9920827
https://pubmed.ncbi.nlm.nih.gov/9920827